

# Deirdre A Lane

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5079025/deirdre-a-lane-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

308  
papers

28,086  
citations

74  
h-index

164  
g-index

360  
ext. papers

35,363  
ext. citations

5.5  
avg, IF

7.29  
L-index

#	Paper	IF	Citations
308	Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. <i>Chest</i> , <b>2010</b> , 137, 263-72	5.3	4353
307	A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. <i>Chest</i> , <b>2010</b> , 138, 1093-100	5.3	2947
306	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Document with the special contribution of the European Heart Rhythm Association (EHRA) of the	9.5	1676
305	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , <b>2018</b> , 39, 1330-1393	9.5	1094
304	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , <b>2015</b> , 17, 1467-507	3.9	803
303	Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , <b>2012</b> , 141, e531S-e575S	5.3	763
302	Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 57, 173-80	15.1	721
301	Stroke and bleeding in atrial fibrillation with chronic kidney disease. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 625-35	59.2	624
300	Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. <i>Chest</i> , <b>2018</b> , 154, 1121-1201	5.3	502
299	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by Association for European Paediatric and Congenital Cardiology (APCC) and the European Association of Cardiovascular Imaging (EACVI)	3.9	426
298	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular	9.5	413
297	Quality of life in patients with atrial fibrillation: a systematic review. <i>American Journal of Medicine</i> , <b>2006</b> , 119, 448.e1-19 (HRS) and Asia-Pacific Heart Rhythm So. <i>European Heart Journal</i> , <b>2014</b> , 35, 3155-75	2.4	372
296	Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. <i>Stroke</i> , <b>2010</b> , 41, 2731-8	6.7	368
295	Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a Real world Pnationwide cohort study. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 106, 739-49	7	332
294	Atrial fibrillation. <i>Lancet, The</i> , <b>2012</b> , 379, 648-61	40	287
293	Mortality and quality of life 12 months after myocardial infarction: effects of depression and anxiety. <i>Psychosomatic Medicine</i> , <b>2001</b> , 63, 221-30	3.7	282
292	The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. <i>Chest</i> , <b>2012</b> , 142, 1489-1498	5.3	281

291	Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 60, 861-7	15.1	265
290	Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. <i>Circulation</i> , <b>2012</b> , 126, 860-5	16.7	259
289	Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a Real world Atrial fibrillation population: a modelling analysis based on a nationwide cohort study. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 107, 584-9	7	239
288	A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. <i>Journal of Thrombosis and Haemostasis</i> , <b>2011</b> , 9, 39-48	15.4	193
287	Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 314, 1030-8	27.4	192
286	Stroke prevention in atrial fibrillation: a systematic review. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 1950-62	27.4	187
285	Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 106, 997-1011	7	184
284	Depression, anxiety, and quality of life in patients with atrial fibrillation. <i>Chest</i> , <b>2007</b> , 132, 1259-64	5.3	182
283	Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. <i>PLoS Medicine</i> , <b>2020</b> , 17, e1003321	11.6	179
282	Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. <i>BMJ, The</i> , <b>2015</b> , 351, h4451	5.9	172
281	Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 56, 827-37	15.1	168
280	Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. <i>Europace</i> , <b>2011</b> , 13, 723-46	3.9	166
279	Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 57, 1339-48	15.1	156
278	Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. <i>Europace</i> , <b>2012</b> , 14, 8-27	3.9	156
277	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. <i>Europace</i> , <b>2018</b> , 20, 1231-1242	3.9	148
276	Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 2365-2375	15.1	142
275	Device-detected subclinical atrial tachyarrhythmias: definition, implications and management-an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulaci3n Cardíaca y Electrofisiologí (SOLAECE). <i>Europace</i> , <b>2017</b> , 19, 1555-1578	3.9	137
274	Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Cardíaca y Electrofisiologí (SOLAECE). <i>Europace</i> , <b>2017</b> , 19, 1588-1603	3.9	135

273	Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. <i>PLoS ONE</i> , <b>2013</b> , 8, e74037	3.7	131
272	Predictors of attendance at cardiac rehabilitation after myocardial infarction. <i>Journal of Psychosomatic Research</i> , <b>2001</b> , 51, 497-501	4.1	131
271	Adjusted prognostic association of depression following myocardial infarction with mortality and cardiovascular events: individual patient data meta-analysis. <i>British Journal of Psychiatry</i> , <b>2013</b> , 203, 90-102	5.4	128
270	Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	127
269	Effects of depression and anxiety on mortality and quality-of-life 4 months after myocardial infarction. <i>Journal of Psychosomatic Research</i> , <b>2000</b> , 49, 229-38	4.1	126
268	Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 209-218	7	124
267	Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme. The West Birmingham Atrial Fibrillation Project. <i>International Journal of Cardiology</i> , <b>2006</b> , 110, 354-8	3.2	124
266	The prevalence and persistence of depression and anxiety following myocardial infarction. <i>British Journal of Health Psychology</i> , <b>2002</b> , 7, 11-21	8.3	124
265	Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. <i>Stroke</i> , <b>2006</b> , 37, 2294-300	6.7	119
264	Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: A systematic review and meta-analysis of death and adverse outcomes. <i>International Journal of Cardiology</i> , <b>2016</b> , 203, 660-6	3.2	116
263	Atrial fibrillation. <i>Nature Reviews Disease Primers</i> , <b>2016</b> , 2, 16016	51.1	115
262	Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App Trial. <i>American Journal of Medicine</i> , <b>2017</b> , 130, 1388-1396.	2.4	110
261	Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2015</b> , 13, 495-504	15.4	110
260	Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. <i>Europace</i> , <b>2013</b> , 15, 1540-56	3.9	101
259	Stroke and thromboembolism in atrial fibrillation. <i>Circulation Journal</i> , <b>2012</b> , 76, 2289-304	2.9	100
258	Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 1523-1534	15.1	99
257	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , <b>2021</b> , 23, 1612-1676	3.9	99
256	Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. <i>QJM - Monthly Journal of the Association of Physicians</i> , <b>2014</b> , 107, 955-67	2.7	97

255	A systematic review of the effects of acute psychological stress and physical activity on haemorheology, coagulation, fibrinolysis and platelet reactivity: Implications for the pathogenesis of acute coronary syndromes. <i>Thrombosis Research</i> , <b>2007</b> , 120, 819-47	8.2	97
254	Low-dose spironolactone in the management of resistant hypertension: a surveillance study. <i>Journal of Hypertension</i> , <b>2007</b> , 25, 891-4	1.9	96
253	Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Cardıaca y Electrofisiologıa (SOLEACE). <i>Europace</i> , <b>2015</b> , 17, 1747-69	3.9	94
252	Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?. <i>American Journal of Medicine</i> , <b>2010</b> , 123, 785-9	2.4	92
251	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. <i>Europace</i> , <b>2016</b> , 18, 37-50	3.9	90
250	Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart	3.9	89
249	European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Cardıaca y Electrofisiologia (SOLEACE). <i>Europace</i> , <b>2017</b> , 19, 465-511	3.9	85
248	Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1192-200	12.3	82
247	Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. <i>Chest</i> , <b>2012</b> , 141, 147-153	5.3	82
246	Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 295-301	12.3	81
245	Epidemiology of atrial fibrillation. <i>International Journal of Clinical Practice</i> , <b>2018</b> , 72, e13070	2.9	80
244	Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 110, 1074-9	7	80
243	Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. <i>Clinical Research in Cardiology</i> , <b>2015</b> , 104, 418-29	6.1	77
242	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. <i>Europace</i> , <b>2014</b> , 16, 1655-73	3.9	77
241	Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. <i>Journal of Thrombosis and Haemostasis</i> , <b>2016</b> , 14, 1711-4	15.4	77
240	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. <i>European Heart Journal</i> , <b>2017</b> , 38, 860-868	9.5	75
239	Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin. <i>American Journal of Medicine</i> , <b>2016</b> , 129, 600-7	2.4	75
238	Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (S. Heart) Association and Sociedad Latinoamericana de Estimulaci3n Cardıaca y. <i>Europace</i> , <b>2017</b> , 19, 1757-1758	3.9	75

237	Illness perceptions, affective response, and health-related quality of life in patients with atrial fibrillation. <i>Journal of Psychosomatic Research</i> , <b>2009</b> , 66, 203-10	4.1	75
236	Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC (Atrial Fibrillation Better Care) Pathway. <i>American Journal of Medicine</i> , <b>2018</b> , 131, 1359-1366.e6	2.4	71
235	Atrial Fibrillation and Cognitive Function: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 612-619	15.1	67
234	Improving survival of malignant hypertension patients over 40 years. <i>American Journal of Hypertension</i> , <b>2009</b> , 22, 1199-204	2.3	67
233	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. <i>Europace</i> , <b>2018</b> , 20, 395-407	3.9	66
232	Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. <i>European Heart Journal</i> , <b>2013</b> , 34, 3572-9	9.5	66
231	Effectiveness of Cognitive Behavioral Therapy for Depression and Anxiety in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis. <i>Psychosomatic Medicine</i> , <b>2018</b> , 80, 742-753	2.7	64
230	Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. <i>American Journal of Medicine</i> , <b>2012</b> , 125, 826.e13-23	2.4	62
229	Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 101, 802-805	7	62
228	Effects of cognitive behavioural therapy for depression in heart failure patients: a systematic review and meta-analysis. <i>Heart Failure Reviews</i> , <b>2017</b> , 22, 731-741	5	60
227	Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 106, 1012-9	7	60
226	Performance of the HEMORR 2 HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 61, 386-7	15.1	59
225	Characterisation and validity of inflammatory biomarkers in the prediction of post-operative atrial fibrillation in coronary artery disease patients. <i>Thrombosis and Haemostasis</i> , <b>2010</b> , 104, 122-7	7	58
224	Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2012</b> , 5, 941-8	6.4	58
223	Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 681-95	12.3	57
222	Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation: Nationwide Cohort Study. <i>Stroke</i> , <b>2015</b> , 46, 2168-74	6.7	56
221	Myocardial ischemic events in Real world Patients with atrial fibrillation treated with dabigatran or warfarin. <i>American Journal of Medicine</i> , <b>2014</b> , 127, 329-336.e4	2.4	56
220	Atrial fibrillation as a risk factor for cognitive impairment: a semi-systematic review. <i>QJM - Monthly Journal of the Association of Physicians</i> , <b>2013</b> , 106, 795-802	2.7	56

219	Stroke risk stratification in a "real-world" elderly anticoagulated atrial fibrillation population. <i>Journal of Cardiovascular Electrophysiology</i> , <b>2011</b> , 22, 25-30	2.7	56
218	In-hospital symptoms of depression do not predict mortality 3 years after myocardial infarction. <i>International Journal of Epidemiology</i> , <b>2002</b> , 31, 1179-82	7.8	56
217	Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project. <i>International Journal of Cardiology</i> , <b>2013</b> , 167, 2682-7	3.2	55
216	Impact of advanced age on management and prognosis in atrial fibrillation: insights from a population-based study in general practice. <i>Age and Ageing</i> , <b>2015</b> , 44, 874-8	3	51
215	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. <i>European Heart Journal</i> , <b>2017</b> , 38, 852-859	9.5	50
214	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 1009-22	7	49
213	Alcohol intake and prognosis of atrial fibrillation. <i>Heart</i> , <b>2013</b> , 99, 1093-9	5.1	45
212	Best practice for atrial fibrillation patient education. <i>Current Pharmaceutical Design</i> , <b>2015</b> , 21, 533-43	3.3	45
211	Thromboprophylaxis in atrial fibrillation and association with cognitive decline: systematic review. <i>Age and Ageing</i> , <b>2016</b> , 45, 767-775	3	44
210	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). <i>Europace</i> , <b>2017</b> , 19, 190-225	3.9	44
209	Do depression and anxiety predict recurrent coronary events 12 months after myocardial infarction?. <i>QJM - Monthly Journal of the Association of Physicians</i> , <b>2000</b> , 93, 739-44	2.7	44
208	Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial. <i>American Journal of Medicine</i> , <b>2020</b> , 133, 1195-1202.e2	2.4	44
207	Residual Risk of Stroke and Death in Anticoagulated Patients According to the Type of Atrial Fibrillation: AMADEUS Trial. <i>Stroke</i> , <b>2015</b> , 46, 2523-8	6.7	43
206	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). <i>European Journal of Preventive Cardiology</i> , <b>2017</b> , 24, 1-10	3.9	43
205	Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 109, 328-36	7	43
204	The impact of heart failure and left ventricular dysfunction in predicting stroke, thromboembolism, and mortality in atrial fibrillation patients: a systematic review. <i>Clinical Therapeutics</i> , <b>2014</b> , 36, 1135-44	3.5	42
203	Patients and health professionals' views and experiences of atrial fibrillation and oral-anticoagulant therapy: a qualitative meta-synthesis. <i>Patient Education and Counseling</i> , <b>2012</b> , 88, 330-7	3.1	42
202	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?. <i>Europace</i> , <b>2018</b> , 20, 1399-1421	3.9	41

201	The impact of smoking on thromboembolism and mortality in patients with incident atrial fibrillation: insights from the Danish Diet, Cancer, and Health study. <i>Chest</i> , <b>2014</b> , 145, 559-66	5.3	40
200	Barriers to anticoagulation in patients with atrial fibrillation: changing physician-related factors. <i>Stroke</i> , <b>2008</b> , 39, 7-9	6.7	40
199	Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores. <i>Scientific Reports</i> , <b>2016</b> , 6, 24376	4.9	40
198	European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. <i>Europace</i> , <b>2016</b> , 18, 12-36	3.9	37
197	Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. <i>European Journal of Internal Medicine</i> , <b>2018</b> , 55, 28-34	3.9	37
196	Mobile Health (mHealth) technology for improved screening, patient involvement and optimising integrated care in atrial fibrillation: The mAFA (mAF-App) II randomised trial. <i>International Journal of Clinical Practice</i> , <b>2019</b> , 73, e13352	2.9	36
195	Comprehensive Management With the ABC (Atrial Fibrillation Better Care) Pathway in Clinically Complex Patients With Atrial Fibrillation: A Post Hoc Ancillary Analysis From the AFFIRM Trial. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e014932	6	36
194	Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. <i>Europace</i> , <b>2017</b> , 19, 139-163	3.9	36
193	Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. <i>American Journal of Medicine</i> , <b>2014</b> , 127, 1172-8.e5	2.4	36
192	Simplifying stroke risk stratification in atrial fibrillation patients: implications of the CHA2DS2-VASc risk stratification scores. <i>Age and Ageing</i> , <b>2010</b> , 39, 533-5	3	36
191	Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines. <i>Canadian Journal of Cardiology</i> , <b>2019</b> , 35, 619-633	3.8	35
190	Stroke and bleeding risk in atrial fibrillation: navigating the alphabet soup of risk-score acronyms (CHADS2, CHA2DS2-VASc, R2 CHADS2, HAS-BLED, ATRIA, and more). <i>Clinical Cardiology</i> , <b>2014</b> , 37, 634-44	3.4	35
189	Home-based versus hospital-based cardiac rehabilitation after myocardial infarction or revascularisation: design and rationale of the Birmingham Rehabilitation Uptake Maximisation Study (BRUM): a randomised controlled trial [ISRCTN72884263]. <i>BMC Cardiovascular Disorders</i> , <b>2003</b> , 3, 10	2.3	35
188	The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review. <i>Journal of Thrombosis and Haemostasis</i> , <b>2013</b> , 11, 975-87	15.4	34
187	Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. <i>Cochrane Database of Systematic Reviews</i> , <b>2013</b> , CD008600		34
186	Bleeding Risk Scores in Atrial Fibrillation and Venous Thromboembolism. <i>American Journal of Cardiology</i> , <b>2017</b> , 120, 1139-1145	3	32
185	Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. <i>The Cochrane Library</i> , <b>2017</b> , 4, CD008600	5.2	31
184	Improving the Prescription of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 294-307	7	31



183	Patients and physicians' experiences of atrial fibrillation consultations and anticoagulation decision-making: A multi-perspective IPA design. <i>Psychology and Health</i> , <b>2016</b> , 31, 436-55	2.9	31
182	Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort. <i>British Journal of General Practice</i> , <b>2015</b> , 65, e16-23	1.6	31
181	Stroke prevention with oral anticoagulation therapy in patients with atrial fibrillation--focus on the elderly. <i>Circulation Journal</i> , <b>2013</b> , 77, 1380-8	2.9	31
180	Efficacy and safety of non-vitamin K antagonist oral anticoagulants vs. warfarin in Japanese patients with atrial fibrillation [meta-analysis]. <i>Circulation Journal</i> , <b>2015</b> , 79, 339-45	2.9	30
179	Quality of life in older people with atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , <b>2009</b> , 25, 37-42	2.4	30
178	Alcohol and illicit drug use as precipitants of atrial fibrillation in young adults: a case series and literature review. <i>American Journal of Medicine</i> , <b>2009</b> , 122, 851-856.e3	2.4	30
177	Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS). <i>Europace</i> , <b>2019</b>	3.9	30
176	The value of the European society of cardiology guidelines for refining stroke risk stratification in patients with atrial fibrillation categorized as low risk using the anticoagulation and risk factors in atrial fibrillation stroke score: a nationwide cohort study. <i>Chest</i> , <b>2014</b> , 146, 1337-1346	5.3	29
175	Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart)	7	29
174	Stroke and bleeding risk in atrial fibrillation. <i>Korean Circulation Journal</i> , <b>2014</b> , 44, 281-90	2.2	29
173	Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials. <i>EBioMedicine</i> , <b>2016</b> , 8, 309-316	8.8	28
172	Guideline-Adherent Antithrombotic Treatment Improves Outcomes in Patients With Atrial Fibrillation: Insights From the Community-Based Darlington Atrial Fibrillation Registry. <i>Mayo Clinic Proceedings</i> , <b>2017</b> , 92, 1203-1213	6.4	28
171	Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a real-world community cohort of patients with atrial fibrillation. <i>European Journal of Clinical Investigation</i> , <b>2013</b> , 43, 1032-8	4.6	28
170	Psychological interventions for depression in heart failure. <i>The Cochrane Library</i> , <b>2005</b> , CD003329	5.2	28
169	Patient-Reported Outcomes for Quality of Life Assessment in Atrial Fibrillation: A Systematic Review of Measurement Properties. <i>PLoS ONE</i> , <b>2016</b> , 11, e0165790	3.7	28
168	Incident Heart Failure in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7,	6	27
167	Matrix metalloproteinases and their tissue inhibitors in hypertension-related pregnancy complications. <i>Journal of Human Hypertension</i> , <b>2013</b> , 27, 72-8	2.6	27
166	Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study. <i>Chest</i> , <b>2013</b> , 144, 1839-1847	5.3	27

165	Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers safe in pregnancy: a report of ninety-one pregnancies. <i>Journal of Hypertension</i> , <b>2011</b> , 29, 396-9	1.9	27
164	Cognitive Behavioral Therapy for Depression, Anxiety, and Stress in Caregivers of Dementia Patients: A Systematic Review and Meta-Analysis. <i>Gerontologist, The</i> , <b>2019</b> , 59, e343-e362	5	27
163	Self-reported physical activity and major adverse events in patients with atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. <i>Europace</i> , <b>2017</b> , 19, 535-543	3.9	26
162	Patients' experiences of atrial fibrillation and non-vitamin K antagonist oral anticoagulants (NOACs), and their educational needs: A qualitative study. <i>Thrombosis Research</i> , <b>2017</b> , 153, 19-27	8.2	25
161	TRial of an Educational intervention on patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT). <i>BMC Cardiovascular Disorders</i> , <b>2010</b> , 10, 21	2.3	25
160	Circulating endothelial cells, arterial stiffness, and cardiovascular risk stratification in hypertension. <i>Chest</i> , <b>2007</b> , 132, 1540-7	5.3	25
159	European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Cardiac y Electrofisiologia (SOLAECE). <i>European Heart Journal</i> , <b>2013</b> , 39, 1442-1445	9.5	24
158	Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study. <i>Netherlands Heart Journal</i> , <b>2013</b> , 21, 354-63	2.2	23
157	Recent developments in understanding epidemiology and risk determinants of atrial fibrillation as a cause of stroke. <i>Canadian Journal of Cardiology</i> , <b>2013</b> , 29, S4-S13	3.8	23
156	Endothelial dysfunction in hypertension in pregnancy: associations between circulating endothelial cells, circulating progenitor cells and plasma von Willebrand factor. <i>Clinical Research in Cardiology</i> , <b>2011</b> , 100, 531-7	6.1	23
155	Quality indicators for the care and outcomes of adults with atrial fibrillation. <i>Europace</i> , <b>2021</b> , 23, 494-495	5.9	23
154	Use of leadless pacemakers in Europe: results of the European Heart Rhythm Association survey. <i>Europace</i> , <b>2018</b> , 20, 555-559	3.9	22
153	Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: Is clopidogrel any safer than aspirin when combined with warfarin?. <i>Thrombosis and Haemostasis</i> , <b>2008</b> , 100, 955-957	7	22
152	Recruitment of ethnic minority patients to a cardiac rehabilitation trial: the Birmingham Rehabilitation Uptake Maximisation (BRUM) study [ISRCTN72884263]. <i>BMC Medical Research Methodology</i> , <b>2005</b> , 5, 18	4.7	22
151	Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review. <i>Health Technology Assessment</i> , <b>2013</b> , 17, 1-188	4.4	22
150	Atrial fibrillation patient preferences for oral anticoagulation and stroke knowledge: Results of a conjoint analysis. <i>Clinical Cardiology</i> , <b>2018</b> , 41, 855-861	3.3	21
149	Relation of Nonvalvular Atrial Fibrillation to Body Mass Index (from the SPORTIF Trials). <i>American Journal of Cardiology</i> , <b>2016</b> , 118, 72-8	3	21
148	Treatment of hypertension in peripheral arterial disease. <i>The Cochrane Library</i> , <b>2013</b> , CD003075	5.2	20

147	Bleeding risk in patients with atrial fibrillation: the AMADEUS study. <i>Chest</i> , <b>2011</b> , 140, 146-155	5.3	20
146	Psychological interventions for depression in adolescent and adult congenital heart disease. <i>The Cochrane Library</i> , <b>2013</b> , CD004372	5.2	19
145	Can we IMPROVE bleeding risk assessment for acutely ill, hospitalized medical patients?. <i>Chest</i> , <b>2011</b> , 139, 10-3	5.3	19
144	Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 27-35	7	18
143	Secondary Versus Primary Stroke Prevention in Atrial Fibrillation: Insights From the Darlington Atrial Fibrillation Registry. <i>Stroke</i> , <b>2017</b> , 48, 2198-2205	6.7	17
142	Gender differences in stroke prevention in atrial fibrillation in general practice: using the GRASP-AF audit tool. <i>International Journal of Clinical Practice</i> , <b>2015</b> , 69, 840-5	2.9	17
141	RCPE UK Consensus Conference on Approaching the comprehensive management of atrial fibrillation: evolution or revolution?P. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , <b>2012</b> , 42, 34-5	0.9	17
140	Amiloride 10 mg is less effective than spironolactone 25 mg in patients with hypertension resistant to a multidrug regime including an angiotensin-blocking agent. <i>Journal of Hypertension</i> , <b>2007</b> , 25, 2515-6 <sup>1.9</sup>	1.9	17
139	Bleeding risk stratification models in deciding on anticoagulation in patients with atrial fibrillation: a useful complement to stroke risk stratification schema. <i>Chest</i> , <b>2006</b> , 130, 1296-9	5.3	17
138	Use of the SAME-TTR score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients receiving vitamin K antagonists: A review. <i>Heart Rhythm</i> , <b>2018</b> , 15, 615-623	6.7	17
137	The Euro Heart Survey and EURObservational Research Programme (EORP) in atrial fibrillation registries: contribution to epidemiology, clinical management and therapy of atrial fibrillation patients over the last 20 years. <i>Internal and Emergency Medicine</i> , <b>2020</b> , 15, 1183-1192	3.7	16
136	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?. <i>Heart Rhythm</i> , <b>2018</b> , 15, e37-e60	6.7	16
135	Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial. <i>Journal of Internal Medicine</i> , <b>2018</b> , 283, 282-292	10.8	16
134	An evaluation of the Minnesota Living with Heart Failure Questionnaire using Rasch analysis. <i>Quality of Life Research</i> , <b>2014</b> , 23, 1753-65	3.7	16
133	Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group. <i>European Heart Journal</i> , <b>2020</b> , 41, 1132-1140	9.5	16
132	2021 ISHNE/HRS/EHRA/APHRS Expert Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2021</b> , 15, e010000	6.4	16
131	Prevalence and clinical outcomes of myocarditis and pericarditis in 718,365 COVID-19 patients. <i>European Journal of Clinical Investigation</i> , <b>2021</b> , 51, e13679	4.6	16
130	Maintaining therapeutic anticoagulation: the importance of keeping "within range". <i>Chest</i> , <b>2007</b> , 131, 1277-9	5.3	15

129	Stroke and death in elderly patients with atrial fibrillation in Japan compared with the United Kingdom. <i>Heart</i> , <b>2016</b> , 102, 1878-1882	5.1	15
128	Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 101, 802-5	7	15
127	International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial Descriptives. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	14
126	The ATRIA risk scheme to predict warfarin-associated hemorrhage not ready for clinical use. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 194-5; author reply 195	15.1	14
125	Anti-thrombotic therapy for atrial fibrillation and patients' preferences for treatment. <i>Age and Ageing</i> , <b>2005</b> , 34, 1-3	3	14
124	Real-world observational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS). <i>Europace</i> , <b>2016</b> , 18, 168-72	3.9	14
123	Relation of the SAME-TT2R2 score to quality of anticoagulation control and thromboembolic events in atrial fibrillation patients: Observations from the SPORTIF trials. <i>International Journal of Cardiology</i> , <b>2016</b> , 216, 168-72	3.2	14
122	Etiologic Workup in Cases of Cryptogenic Stroke: A Systematic Review of International Clinical Practice Guidelines. <i>Stroke</i> , <b>2020</b> , 51, 1419-1427	6.7	13
121	Net clinical benefit of edoxaban versus no treatment in a real world atrial fibrillation population: A modelling analysis based on a nationwide cohort study. <i>International Journal of Cardiology</i> , <b>2015</b> , 201, 693-8	3.2	13
120	Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic. <i>International Journal of Clinical Practice</i> , <b>2015</b> , 69, 1341-8	2.9	13
119	Assessment of stroke risk in Middle Eastern patients with atrial fibrillation: the Gulf SAFE registry. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 1644-6	3.2	13
118	Temporal and venepuncture-related decline in circulating endothelial cell capture from mixed venous blood. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2006</b> , 22, 125-31	5.1	13
117	A bifactor model of the Beck Depression Inventory and its association with medical prognosis after myocardial infarction. <i>Health Psychology</i> , <b>2016</b> , 35, 614-24	5	13
116	Adolescents and Young Adults' Lived Experiences Following Venous Thromboembolism: "It will always lie in wait". <i>Nursing Research</i> , <b>2016</b> , 65, 455-464	1.9	13
115	Beyond the 2020 guidelines on atrial fibrillation of the European society of cardiology. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 86, 1-11	3.9	12
114	Mobile Apps to Improve Medication Adherence in Cardiovascular Disease: Systematic Review and Meta-analysis. <i>Journal of Medical Internet Research</i> , <b>2021</b> , 23, e24190	7.6	12
113	Educational Impact on Apixaban Adherence in Atrial Fibrillation (the AEGEAN STUDY): A Randomized Clinical Trial. <i>American Journal of Cardiovascular Drugs</i> , <b>2020</b> , 20, 61-71	4	12
112	Clinical Features and Prognosis in Patients with Atrial Fibrillation and Prior Stroke: Comparing the Fushimi and Darlington AF Registries. <i>EBioMedicine</i> , <b>2017</b> , 18, 199-203	8.8	11

111	Use of psychotropic drugs following venous thromboembolism in youth. A nationwide cohort study. <i>Thrombosis Research</i> , <b>2015</b> , 135, 643-7	8.2	11
110	Contra: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation". <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 102, 914-5	7	11
109	Mobile health applications for managing atrial fibrillation for healthcare professionals and patients: a systematic review. <i>Europace</i> , <b>2020</b> ,	3.9	11
108	Atrial fibrillation and the risk of 30-day incident thromboembolic events, and mortality in adults $\geq 50$ years with COVID-19. <i>Journal of Arrhythmia</i> , <b>2021</b> , 37, 231-237	1.5	11
107	Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation. <i>Circulation</i> , <b>2015</b> , 131, e412-5	16.7	10
106	Female sex as a risk factor for thromboembolism and death in patients with incident atrial fibrillation. The prospective Danish Diet, Cancer and Health study. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 789-95	7	10
105	2021 ISHNE/ HRS/ EHRA/ APHRS collaborative statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia Pacific Heart Rhythm Society. <i>Annals of Noninvasive Electrocardiology</i> , <b>2021</b> , 26, e12795	1.5	10
104	Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 54	4.9	9
103	Atrial fibrillation and heart failure: a bad combination. <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 1196-73		9
102	Streamlining primary and secondary care management pathways for stroke prevention in atrial fibrillation. <i>European Heart Journal</i> , <b>2017</b> , 38, 2980-2982	9.5	9
101	Impact of symptom control on health-related quality of life in atrial fibrillation patients: the psychologist's viewpoint. <i>Europace</i> , <b>2010</b> , 12, 608-10	3.9	9
100	Patients' Perceptions of Atrial Fibrillation, Stroke Risk, and Oral Anticoagulation Treatment: An International Survey. <i>TH Open</i> , <b>2018</b> , 2, e233-e241	2.7	9
99	Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey. <i>Europace</i> , <b>2019</b> , 21, 1116-1125	3.9	8
98	Innovative strategies to improve adherence to non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation. <i>European Heart Journal</i> , <b>2018</b> , 39, 1404-1406	9.5	8
97	The quest for new anticoagulants: from clinical development to clinical practice. <i>Cardiovascular Therapeutics</i> , <b>2011</b> , 29, e12-22	3.3	8
96	Angiogenin and hemoxygenase in pregnancy: influence of hypertension. <i>Angiology</i> , <b>2012</b> , 63, 194-8	2.1	8
95	Dabigatran in atrial fibrillation: balancing secondary stroke prevention against bleeding risk. <i>Lancet Neurology</i> , <b>2010</b> , 9, 1140-1142	24.1	8
94	Cross-cultural adaptation into Punjabi of the English version of the Hospital Anxiety and Depression Scale. <i>BMC Psychiatry</i> , <b>2007</b> , 7, 5	4.2	8

93	Lipid levels, atrial fibrillation and the impact of age: Results from the LIPIDOGram2015 study. <i>Atherosclerosis</i> , <b>2020</b> , 312, 16-22	3.1	8
92	The Compelling Issue of Nonvitamin K Antagonist Oral Anticoagulant Adherence in Atrial Fibrillation Patients: A Systematic Need for New Strategies. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 3697-3717	7	7
91	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice?. <i>Journal of Arrhythmia</i> , <b>2018</b> , 34, 99-123	1.5	7
90	Stroke risk stratification scores in atrial fibrillation: current recommendations for clinical practice and future perspectives. <i>Expert Review of Cardiovascular Therapy</i> , <b>2013</b> , 11, 77-90	2.5	7
89	Soluble Fas and Fas ligand in pregnancy: influence of hypertension. <i>Angiology</i> , <b>2012</b> , 63, 35-8	2.1	7
88	Treatment of hypertension in peripheral arterial disease. <i>Cochrane Database of Systematic Reviews</i> , <b>2009</b> , CD003075		7
87	Higher Mortality of Ischaemic Stroke Patients Hospitalized with COVID-19 Compared to Historical Controls. <i>Cerebrovascular Diseases</i> , <b>2021</b> , 50, 326-331	3.2	7
86	Clinicians' views and experiences of prescribing oral anticoagulants for stroke prevention in atrial fibrillation: A qualitative meta-synthesis. <i>PLoS ONE</i> , <b>2020</b> , 15, e0232484	3.7	6
85	Anticoagulation control in different ethnic groups receiving vitamin K antagonist therapy for stroke prevention in atrial fibrillation. <i>Thrombosis Research</i> , <b>2020</b> , 192, 12-20	8.2	6
84	Peri-procedural management, implantation feasibility, and short-term outcomes in patients undergoing implantation of leadless pacemakers: European Snapshot Survey. <i>Europace</i> , <b>2020</b> , 22, 833-838	3.9	6
83	Individual depressive symptoms and all-cause mortality in 6673 patients with myocardial infarction: Heterogeneity across age and sex subgroups. <i>Journal of Affective Disorders</i> , <b>2018</b> , 228, 178-185	6.6	6
82	Impaired glucose tolerance and endothelial damage, as assessed by levels of von Willebrand factor and circulating endothelial cells, following acute myocardial infarction. <i>Annals of Medicine</i> , <b>2009</b> , 41, 608-18	1.5	6
81	Lack of impact of pulse pressure on outcomes in patients with malignant phase hypertension: the West Birmingham Malignant Hypertension study. <i>Journal of Hypertension</i> , <b>2012</b> , 30, 974-9	1.9	6
80	Challenges facing anticoagulation among the elderly and frail. <i>Age and Ageing</i> , <b>2009</b> , 38, 140-2	3	6
79	Sex differences in clinical characteristics and inpatient outcomes among 2442 hospitalized Chinese patients with nonvalvular atrial fibrillation: The Nanchang Atrial Fibrillation Project. <i>International Journal of Cardiology</i> , <b>2015</b> , 201, 195-9	3.2	5
78	Stroke risk reduction with oral anticoagulation using CHA2DS2-VASc in a Japanese AF population: A modeling analysis. <i>International Journal of Cardiology</i> , <b>2015</b> , 181, 247-54	3.2	5
77	Guideline-adherent secondary prevention post-acute coronary syndromes: the importance of patient uptake and persistence. <i>European Heart Journal</i> , <b>2018</b> , 39, 2365-2367	9.5	5
76	Letter by Apostolakis et al regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts". <i>Circulation</i> , <b>2013</b> , 128, e171	16.7	5

75	Angiogenin and apoptosis in hypertension in pregnancy. <i>Pregnancy Hypertension</i> , <b>2011</b> , 1, 191-6	2.6	5
74	Anticoagulation for atrial fibrillation patients with CHADS score of 1. <i>Journal of Cardiovascular Electrophysiology</i> , <b>2010</b> , 21, 508-10	2.7	5
73	Atrial fibrillation and mortality: the impact of antithrombotic therapy. <i>European Heart Journal</i> , <b>2010</b> , 31, 2075-6	9.5	5
72	Bleeding rates in elderly patients on vitamin K antagonist therapy for nonvalvular atrial fibrillation. <i>Blood Coagulation and Fibrinolysis</i> , <b>2009</b> , 20, 392-3	1	5
71	Atrial fibrillation and stroke risk prevention in real-life clinical practice. <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 101, 415-416	7	5
70	Stroke and bleeding risk stratification in atrial fibrillation: a critical appraisal. <i>European Heart Journal Supplements</i> , <b>2020</b> , 22, O14-O27	1.5	5
69	Utilization and perception of same-day discharge in electrophysiological procedures and device implantations: an EHRA survey. <i>Europace</i> , <b>2021</b> , 23, 149-156	3.9	5
68	Developing a Complex Educational-Behavioural Intervention: The TREAT Intervention for Patients with Atrial Fibrillation. <i>Healthcare (Switzerland)</i> , <b>2016</b> , 4,	3.4	5
67	Guideline-Adherent Treatment for Stroke and Death in Atrial Fibrillation Patients From UK and Japanese AF Registries. <i>Circulation Journal</i> , <b>2019</b> , 83, 2434-2442	2.9	4
66	Oral anticoagulants for stroke prevention in atrial fibrillation. <i>Current Problems in Cardiology</i> , <b>2014</b> , 39, 319-44	17.1	4
65	Obstructive Sleep Apnea Is a Risk Factor for Stroke and Atrial Fibrillation: Response. <i>Chest</i> , <b>2010</b> , 138, 239-240	5.3	4
64	Stroke prevention in atrial fibrillation patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2010</b> , 11, 2331-50	4	4
63	Short-term effects of screening for cardiovascular risk in the deaf community: a pilot study. <i>Cardiology Research and Practice</i> , <b>2011</b> , 2011, 493546	1.9	4
62	Psychological interventions for depression in adolescent and adult congenital heart disease <b>2003</b> ,		4
61	Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry. <i>BMC Medicine</i> , <b>2021</b> , 19, 256	11.4	4
60	The Atrial Fibrillation Better Care pathway for managing atrial fibrillation: a review. <i>Europace</i> , <b>2021</b> , 23, 1511-1527	3.9	4
59	Exercise-Based Cardiac Rehabilitation and All-Cause Mortality Among Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e020804	6	4
58	The importance of adherence and persistence with oral anticoagulation treatment in patients with atrial fibrillation. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> , 7, f81-f83	6.4	4

57	Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 1	6.1	4
56	Mobile health solutions for atrial fibrillation detection and management: a systematic review. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 1	6.1	4
55	The Effects of Implementing a Mobile Health-Technology Supported Pathway on Atrial Fibrillation-Related Adverse Events Among Patients With Multimorbidity: The mAFA-II Randomized Clinical Trial.. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2140071	10.4	4
54	Considerations when choosing an appropriate bleeding risk assessment tool for patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 788-790	15.4	3
53	Optimising stroke prevention in patients with atrial fibrillation. <i>British Journal of General Practice</i> , <b>2015</b> , 65, 117	1.6	3
52	Comparative Analysis of the HAS-BLED Score With Other Bleeding Risk Scores, Using Estimates of Net Reclassification Improvement and Integrated Discrimination Improvement. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 58, 1398-1399	15.1	3
51	Quality of anticoagulation control in atrial fibrillation. <i>Lancet, The</i> , <b>2010</b> , 376, 935-7	4.0	3
50	Anticoagulation control with vitamin K antagonists: how well are we doing?. <i>Chest</i> , <b>2006</b> , 129, 1122-4	5.3	3
49	Atrial fibrillation in low- and middle-income countries: a narrative review. <i>European Heart Journal Supplements</i> , <b>2020</b> , 22, O61-O77	1.5	3
48	Guía ESC 2020 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración de la European Association of Cardio-Thoracic Surgery (EACTS). <i>Revista Espanola De Cardiologia</i> , <b>2021</b> , 74, 437.e1-437.e116	1.5	3
47	Executive Summary: European Heart Rhythm Association Consensus Document on the Management of Supraventricular Arrhythmias: Endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca	3.2	3
46	2021 ISHNE/HRS/EHRA/APHRS collaborative statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia Pacific Heart Rhythm Society. <i>Journal of Arrhythmia and Electrophysiology</i> , <b>2021</b> , 5, 210-224	1.5	3
45	Mobile health technology facilitates population screening and integrated care management in patients with atrial fibrillation. <i>European Heart Journal</i> , <b>2020</b> , 41, 1617-1619	9.5	2
44	ACP Journal Club. The 5-factor ORBIT bleeding score predicted major bleeding at 2 years in patients with atrial fibrillation. <i>Annals of Internal Medicine</i> , <b>2016</b> , 164, JC11	8	2
43	Integrated care for the management of atrial fibrillation: what are the key components and important outcomes?. <i>Europace</i> , <b>2019</b> , 21, 1759-1761	3.9	2
42	Use of the HAS-BLED bleeding score in real-life settings. <i>Thrombosis Research</i> , <b>2014</b> , 134, 202	8.2	2
41	Does obesity influence target organ damage and outcomes in patients with malignant phase hypertension? The West Birmingham Malignant Hypertension Project. <i>Hypertension Research</i> , <b>2013</b> , 36, 546-9	4.7	2
40	The assessment of stroke and bleeding risk in atrial fibrillation: where are we now?. <i>Expert Review of Cardiovascular Therapy</i> , <b>2010</b> , 8, 1703-10	2.5	2



39	CHA 2 DS 2 -VAsC Risk Scheme: Response. <i>Chest</i> , <b>2010</b> , 138, 1020-1021	5.3	2
38	The HAS-BLED Score and Renal Failure: Response. <i>Chest</i> , <b>2011</b> , 139, 1249-1250	5.3	2
37	Vital exhaustion and cardiovascular disease: are circulating fibrinogen and D-dimer levels a plausible link?. <i>Stress</i> , <b>2008</b> , 11, 247-9	3	2
36	Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease. <i>Current Medicinal Chemistry</i> , <b>2016</b> , 23, 2055-69	4.3	2
35	Prevalence of atrial fibrillation and outcomes in older long-term care residents: a systematic review. <i>Age and Ageing</i> , <b>2021</b> , 50, 744-757	3	2
34	Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials. <i>European Heart Journal Supplements</i> , <b>2020</b> , 22, 11-112	1.5	2
33	Psychotropic drug use following venous thromboembolism versus diabetes mellitus in adolescence or young adulthood: a Danish nationwide cohort study. <i>BMJ Open</i> , <b>2019</b> , 9, e026159	3	2
32	Etiologic workup in cases of cryptogenic stroke: protocol for a systematic review and comparison of international clinical practice guidelines. <i>Systematic Reviews</i> , <b>2019</b> , 8, 331	3	2
31	2021 ISHNE/HRS/EHRA/APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia Pacific Heart Rhythm Society.. <i>Cardiovascular Digital Health Journal</i> , <b>2021</b> , 2, 4-54	2	2
30	Qualitative exploration of the effect of a television soap opera storyline on women with experience of postpartum psychosis. <i>BJPsych Open</i> , <b>2018</b> , 4, 75-82	5	2
29	Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Stroke.. <i>Stroke</i> , <b>2022</b> , STROKEAHA121037316	6.7	2
28	Composite end point analyses of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , <b>2015</b> , 13, 1155-63	2.5	1
27	Assessing Eligibility for Anticoagulation After Diagnosis of Atrial Fibrillation--Reply. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 314, 949-50	27.4	1
26	Balancing thromboembolism and bleeding risks: insights from anticoagulation for prosthetic heart valves. <i>Chest</i> , <b>2009</b> , 136, 1451-1452	5.3	1
25	Atrial fibrillation (chronic). <i>Clinical Evidence</i> , <b>2011</b> , 2011,		1
24	Atrial fibrillation (chronic). <i>Clinical Evidence</i> , <b>2015</b> , 2015,		1
23	Prospective randomised trial examining the impact of an educational intervention versus usual care on anticoagulation therapy control based on an SAME-TTR score-guided strategy in anticoagulant-naïve Thai patients with atrial fibrillation (TREATS-AF): a study protocol. <i>BMJ Open</i> , <b>2021</b> , 11, e051987	3	1
22	Patient Satisfaction: A Key Component in Increasing Treatment Adherence and Persistence. <i>Thrombosis and Haemostasis</i> , <b>2021</b> , 121, 255-257	7	1

21	Associations between COVID-19 and 30-day thromboembolic events and mortality in people with dementia receiving antipsychotic medications. <i>Pharmacological Research</i> , <b>2021</b> , 167, 105534	10.2	1
20	End-Stage renal disease and 30-day mortality for adults with and without COVID-19. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 83, 93-95	3.9	1
19	Association of Exercise-Based Cardiac Rehabilitation with Progression of Paroxysmal to Sustained Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
18	2021 ISHNE / HRS / EHRA / APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals From the International Society for Holter and Noninvasive Electrocardiology / Heart Rhythm Society / European Heart Rhythm Association. <i>Frontiers in Digital Health</i> , <b>2021</b> , 2, 748	2.3	1
17	Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry.. <i>European Journal of Clinical Investigation</i> , <b>2022</b> , e13773	4.6	1
16	Risk of Cerebrovascular Events in Intracerebral Hemorrhage Survivors With Atrial Fibrillation: A Nationwide Cohort Study.. <i>Stroke</i> , <b>2022</b> , 101161STROKEAHA121038331	6.7	1
15	Lifestyle and risk factor modification for reduction of atrial fibrillation: We could do more. <i>Trends in Cardiovascular Medicine</i> , <b>2020</b> , 30, 387-388	6.9	0
14	Validation of the modified Microlife blood pressure monitor in patients with paroxysmal atrial fibrillation. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 802-809	6.1	0
13	Optimization of atrial fibrillation care: management strategies and quality measures. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , <b>2021</b> , 7, 121-133	4.6	0
12	Antithrombotic therapy for stroke prevention in patients with atrial fibrillation who survive an intracerebral haemorrhage: results of an EHRA survey. <i>Europace</i> , <b>2021</b> , 23, 806-814	3.9	0
11	Modelling of longitudinal data to predict cardiovascular disease risk: a methodological review.. <i>BMC Medical Research Methodology</i> , <b>2021</b> , 21, 283	4.7	0
10	The Liverpool Centre for Cardiovascular Science. <i>European Heart Journal</i> , <b>2019</b> , 40, 957-958	9.5	
9	Letter by Guo et al Regarding Article, "SUPPORT-AF II: Supporting Use of Anticoagulants Through Provider Profiling of Oral Anticoagulant Therapy for Atrial Fibrillation". <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2020</b> , 13, e006635	5.8	
8	The reply. <i>American Journal of Medicine</i> , <b>2014</b> , 127, e21	2.4	
7	Reply: To PMID 22858389. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 61, 482-483	15.1	
6	To the Editor - Adding renal dysfunction to CHADSEVAsc improves stroke prediction postcatheter ablation. <i>Heart Rhythm</i> , <b>2012</b> , 9, e25; author reply e26	6.7	
5	Assessing the Performance of the HAS-BLED Score: Response. <i>Chest</i> , <b>2011</b> , 139, 1248	5.3	
4	Advances in therapy for atrial fibrillation. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2010</b> , 7, 103-105		

- 3 Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention. *International Journal of Clinical Practice*, **2022**, 2022, 1-8 2.9
- 2 Haemorrhage risks, patient perspectives, and quality-of-life issues **2010**, 35-42
- 1 Hemorrhage Risks, Patient Perspectives, and Quality-of-Life Issues **2013**, 41-51